Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12631829 | 0.84 | CCNA2 (0.32) | — | |
| SCHEMBL12631841 | 0.84 | KMT2A (0.43) | LMNA | |
| SCHEMBL12631795 | 0.74 | AKT1 (0.33) | — | |
| SCHEMBL12631827 | 0.71 | LCK (0.32) | LMNA | |
| SCHEMBL12631824 | 0.68 | MEN1 (0.47) | LMNA | |
| SCHEMBL23823258 | 0.65 | JAK2 (0.43) | — | |
| SCHEMBL22860434 | 0.65 | JAK2 (0.43) | — | |
| SCHEMBL1976614 | 0.64 | KMT2A (0.36) | — | |
| SCHEMBL13510249 | 0.63 | STK17B (0.47) | — | |
| SCHEMBL16120477 | 0.63 | TP53 (0.35) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947694-B2 | Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947694-B2 | Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | CDK1, CDK2, CDKN1A | BRS3 3638/4885LMNA 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.